Lakefront Biotherapeutics N.V.
LKFT | NASDAQ
$32.14
-$0.14 (-0.43%)
Nov 2, 2026, 10:35 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
Revenue | 1.11B | 275.65M | 239.72M | 241.25M | 234.38M |
Cost of Revenue | 29.74M | 34.86M | n/a | n/a | 320.5M |
Gross Profit | 1.08B | 240.79M | 239.72M | 241.25M | -86.12M |
Operating Income | 501.39M | -188.34M | -88.26M | -131.06M | -171.57M |
Interest Income | 46.34M | 89.77M | 79.61M | 18.09M | n/a |
Pretax Income | 300.87M | -3.09M | 5.63M | -70.85M | -119.4M |
Net Income | 320.88M | 74.08M | 211.7M | -217.99M | -103.23M |
Selling & General & Admin | 111.96M | 96.88M | 94.25M | 103.31M | 131.52M |
Research & Development | 459.42M | 335.46M | 241.29M | 269.8M | 320.5M |
Other Expenses | 9.74M | -3.22M | -7.56M | -801K | -366.57M |
Operating Expenses | 581.12M | 429.12M | 327.99M | 372.31M | 85.45M |
Interest Expense | 2.22M | 911K | 1.77M | 9.16M | 8.73M |
Selling & Marketing Expenses | 1.39M | 2.81M | 1.78M | 1.27M | 3.78M |
Cost & Expenses | 610.86M | 463.99M | 327.99M | 372.31M | 405.95M |
Income Tax Expense | -18.62M | -1.8M | 9.61M | 572K | 1.39M |
Shares Outstanding (Basic) | 65.9M | 66.14M | 65.88M | 65.66M | 55.98M |
Shares Outstanding (Diluted) | 65.9M | 66.14M | 65.88M | 65.66M | 65.5M |
EPS (Basic) | 4.87 | 1.12 | 3.21 | -3.32 | -1.84 |
EPS (Diluted) | 4.87 | 1.12 | 3.21 | -3.32 | -1.84 |
EBITDA | 358.96M | 43.33M | 51.04M | 3.87M | -163.26M |
EBIT | 303.09M | -2.17M | 7.4M | -61.69M | -171.57M |
Depreciation & Amortization | 55.88M | 45.5M | 43.64M | 65.57M | 8.31M |
Add to Watchlist
Select watchlists to add or remove LKFT